Although the EMA says ‘potential links’ found between JAB and ‘abnormal’ blood clots, the UK provides alternative shots to youngsters because of the risk.
The AstraZeneca COID-19 vaccine came under further pressure on Wednesday as it found a possible link between EU drug regulatory shots and rare cases of blood clots, and the UK announced that it had offered young people alternative jobs. Risk.
The much-anticipated ruling by the European Medicines Agency (EMA) on Wednesday follows a review of multiple reports known as Cerebral Venus Sinus Thrombosis (CVST) among the senders of an extremely rare clot in the brain.
As of Sunday, the regulator said it had received reports of 1,169 CVST cases from 34 million doses of shots operated in the European Economic Area.
It was concluded that abnormal blood clots with low blood platelets should be listed as a very rare side effect of the vaccine, but it was recommended that vaccines be continued in adults, reconsidering its position that the benefits of the shot outweigh any risks.
“The EMA is reminding healthcare professionals and people receiving the vaccine to be aware of the possibility of very low cases of low blood platelet synthesis within two weeks of vaccination,” the body said in a statement.
“Most cases reported so far have occurred within two weeks of vaccination in women under the age of 60. The exact cause of the risk could not be ascertained on the basis of the evidence currently available. “
The EMA does not impose any new age restrictions on vaccine use for people 18 years of age or older, as some countries have done.
In a separate development on Wednesday, the UK government’s Vaccine Advisory Group recommended that people between the ages of 18 and 29 should be offered an alternative vaccine to AstraZeneca shots wherever available.
The move comes after the UK’s Independent Medicines and Health Care Regulatory Agency completed its own review of possible links between vaccines and reported blood clots.
The agency’s head, June Rhine, said at the end of March there were nine unusual blood clots in the UK and 19 people had died. More than 20 million doses of AstraZeneca shots have been given nationwide.
Of the cases, 51 were women and 26 were men between the ages of 18 and 7979, Ryan said.
The regulator said that the amount of evidence that AstraZeneca shots were caused by blood clots was not enough, but the addition was becoming more pronounced.
“This is a reasonably causal link, but much more needs to be done to prove our expectations and the scientific understanding of this new constellation of signs,” Rhine said.
Public opinion ‘beaten’
Natasha Butler of Al Jazeera, based in Paris, said Wednesday’s ruling made it clear that “the average person is much more at risk than receiving the COVID-19 astrageneca vaccine.”
He added, however, that the public opinion of the shot has been “shattered” amid fears of blood clots, with the potential impact of taking the job.
“These are the kinds of problems that they have to face now that they want the vaccine to be safe and that these benefits outweigh any risks. European governments will now face them as they try to get the message across.”
“There has been so much damage over the last few weeks and months by negative publicity and controversial information about the AstraZeneca vaccine.”
The AstraZeneca vaccine is important for Europe’s vaccination campaign and is a pillar of the UN-backed COVX program, which aims to introduce the vaccine to some of the world’s poorest countries.
It is cheaper and easier to use than the competitors offered by Pfizer-Bioentech and Modarna and has been approved for use in more than 50 countries.
The World Health Organization has endorsed the shot and has repeatedly said, like the EMA, that its benefits outweigh the potential risks of side effects.